Tag: ILLUMENATE
ILLUMENATE four-year pooled analysis has “brought increased clarity” to the paclitaxel...
Sean Lyden (Cleveland, USA), current VIVA Board president, speaks to Vascular News about his two years at the helm, which began with the “controversy on...
Four-year results from patient-level meta-analysis confirm safety profile of Philips Stellarex...
Royal Philips today announced the results of a patient-level meta-analysis that confirms the safety profile of its Stellarex drug-coated balloon (DCB) at four years....
“Starting to close the door on the paclitaxel controversy”: Late-breaking trials...
Findings from a series of late-breaking trials in the endovascular field were presented recently at TCT Connect (14–18 October, virtual), the 32nd annual scientific...
Late-breaking ILLUMENATE data demonstrate three-year safety and efficacy for Stellarex DCB
Three-year results from the ILLUMENATE Pivotal trial and the ILLUMENATE European randomised controlled trial (EU RCT) have been presented in a late-breaking trial session...
Two-year ILLUMENATE Global data find 72.4% primary patency with Stellarex DCB
After two years of follow-up, the ILLUMENATE Global study has confirmed the durability of the Stellarex drug-coated balloon (Spectranetics/Philips) with primary patency rates comparable...
Two-year efficacy of Philips’ Stellarex 0.035” low-dose drug-coated balloon demonstrated
Philips has announced the two-year results from the ILLUMENATE European randomised clinical trial (EU RCT) demonstrating the efficacy of the Philips Spectranetics’ Stellarex 0.035”...
Spectranetics announces FDA approval of Stellarex drug-coated balloon
Spectranetics has announced receipt of US Food and Drug Administration (FDA) pre-market approval of the Stellarex drug-coated balloon (DCB), designed to restore and maintain blood flow...
Global cohorts report drug-coated balloon success above the knee and “promising”...
Three global registries reported fresh data at the 2017 Leipzig Interventional Course (LINC; 24–27 January, Leipzig, Germany), all of which showed encouraging outcomes for...
Combined 12-month analysis of ILLUMENATE EU and US trials presented at...
At LINC 2017 (24–27 January, Leipzig, Germany), Sean Lyden (Cleveland Clinic, Cleveland, USA) presented an update on the 12-month results of the European and...
Positive results for Spectranetics Stellarex demonstrated in ILLUMENATE 12-month data
The final 12-month results of the Stellarex (Spectranetics) drug-coated balloon ILLUMENATE Global Study have found high primary patency and freedom from clinically driven target...
Spectranetics files FDA pre-market approval application for the Stellarex drug-coated balloon
Spectranetics has submitted its pre-market approval application for the Stellarex drug-coated angioplasty balloon to the US Food and Drug Administration (FDA). Stellarex is designed to restore...
First randomised Stellarex DCB data show 12-month outcomes superior to percutaneous...
Marianne Brodmann of Medical University Graz, Austria, has presented the final 12-month results of the Stellarex (Spectranetics) ILLUMENATE drug-coated balloon European randomised clinical trial...
